☰

Craig R. Stumpf, Ph.D. - Publications

Affiliations: 
University of Wisconsin, Madison, Madison, WI 
Tree Info Grants Similar researchers PubMed Report error

27 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Shukla T, de la Peña JB, Perish JM, Ploski JE, Stumpf CR, Webster KR, Thorn CA, Campbell ZT. A Highly Selective MNK Inhibitor Rescues Deficits Associated with Fragile X Syndrome in Mice. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 33006091 DOI: 10.1007/s13311-020-00932-4  0.626
2019 Xu Y, Poggio M, Jin HY, Shi Z, Forester CM, Wang Y, Stumpf CR, Xue L, Devericks E, So L, Nguyen HG, Griselin A, Gordan JD, Umetsu SE, Reich SH, et al. Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nature Medicine. PMID 30643286 DOI: 10.1038/S41591-018-0321-2  0.364
2019 Young NP, Stumpf CR, Chen J, Chiang GG, Thompson PA, Webster KR. Abstract 4343: A focused CRISPR screen to identify synthetic lethal interactions with the novel eIF4A inhibitor eFT226 in KRAS driven NSCLC Cancer Research. 79: 4343-4343. DOI: 10.1158/1538-7445.Am2019-4343  0.479
2019 Stumpf CR, Goel VK, Sharma RK, Chiang GG, Thompson PA, Webster KR. Abstract 4142: Physical and functional interactions between MNK and mTOR signaling regulate the activation and differentiation of T cells Cancer Research. 79: 4142-4142. DOI: 10.1158/1538-7445.Am2019-4142  0.36
2019 Chiang GG, Parker GS, Hung IN, Goel VK, Staunton J, Barrera M, Sung E, Parra A, Stumpf CR, Chen J, Thompson PA, Nevarez A, Wegerski CJ, Parker C, Clarine J, et al. Abstract 1302: Targeting hormone receptor-dependent cancers with potent, selective and orally-available small molecule inhibitors of eIF4E Cancer Research. 79: 1302-1302. DOI: 10.1158/1538-7445.Am2019-1302  0.33
2019 Thompson PA, Young NP, Stumpf CR, Eam B, Goel VK, Chen J, Fish S, Parker GS, Gerson-Gurwitz A, Barrera M, Sung E, Staunton J, Chiang GG, Wegerski CJ, Sperry S, et al. Abstract B133: eFT226, a first in class inhibitor of eIF4A1, targets FGFR1/2 and HER2 driven cancers Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B133  0.391
2018 Reich SH, Sprengeler PA, Chiang GG, Appleman JR, Chen J, Clarine J, Eam B, Ernst JT, Han Q, Goel VK, Han EZ, Huang V, Hung IN, Jemison A, Jessen KA, ... ... Stumpf CR, et al. Structure-based Design of Pyridone-aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition. Journal of Medicinal Chemistry. PMID 29526098 DOI: 10.1021/Acs.Jmedchem.7B01795  0.432
2018 Stumpf CR, Chen J, Goel VK, Parker GS, Chiang GG, Thompson PA, Webster KR. Abstract 3855: Inhibition of MNK by eFT508 reprograms T-cell signaling to promote an antitumor immune response Cancer Research. 78: 3855-3855. DOI: 10.1158/1538-7445.Am2018-3855  0.379
2017 Webster KR, Goel VK, Staunton J, Hung IN, Parker GS, Stumpf CR, Molter J, Chiang GG, Wegerski CJ, Sperry S, Chen J, Huang V, Thompson PA, Tran C, Ernst JT, et al. Abstract PR11: eFT508: An oral, potent and highly selective inhibitor of MNK1 and MNK2, promotes anti-tumor immunity as a monotherapy and in combination with immune checkpoint blockade Cancer Research. 77. DOI: 10.1158/1538-7445.Transcontrol16-Pr11  0.373
2017 Webster KR, Goel VK, Staunton J, Stumpf CR, Sharma R, Hung IN, Parker GS, Molter J, Chiang GG, Wegerski CJ, Sperry S, Huang V, Chen J, Thompson PA, Tran C, et al. Abstract 596: eFT508, a potent and highly selective inhibitor of MNK1/2 regulates immune checkpoint and cytokine expression promoting anti-tumor immunity Cancer Research. 77: 596-596. DOI: 10.1158/1538-7445.Am2017-596  0.363
2015 Stumpf C, Cunningham T, Ruggero D. Abstract PR07: Myc-dependent translation makes an impact: Tailor-made protein expression for cancer development Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-Pr07  0.4
2013 Stumpf CR, Moreno MV, Olshen AB, Taylor BS, Ruggero D. The translational landscape of the mammalian cell cycle. Molecular Cell. 52: 574-82. PMID 24120665 DOI: 10.1016/J.Molcel.2013.09.018  0.332
2013 Olshen AB, Hsieh AC, Stumpf CR, Olshen RA, Ruggero D, Taylor BS. Assessing gene-level translational control from ribosome profiling. Bioinformatics (Oxford, England). 29: 2995-3002. PMID 24048356 DOI: 10.1093/Bioinformatics/Btt533  0.46
2013 Cunningham JT, Pourdehnad M, Stumpf CR, Ruggero D. Investigating Myc-dependent translational regulation in normal and cancer cells. Methods in Molecular Biology (Clifton, N.J.). 1012: 201-12. PMID 24006066 DOI: 10.1007/978-1-62703-429-6_13  0.442
2013 Stumpf CR, Moreno MV, Olshen AB, Taylor BS, Ruggero D. Abstract A57: Plasticity of the translational landscape during the mammalian cell cycle: Implications and new insights for cancer cell proliferation Cancer Research. 73. DOI: 10.1158/1538-7445.Fbcr13-A57  0.345
2012 Liu Q, Stumpf C, Thomas C, Wickens M, Haag ES. Context-dependent function of a conserved translational regulatory module. Development (Cambridge, England). 139: 1509-21. PMID 22399679 DOI: 10.1242/Dev.070128  0.608
2012 Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 485: 55-61. PMID 22367541 DOI: 10.1038/Nature10912  0.333
2011 Stumpf CR, Ruggero D. The cancerous translation apparatus. Current Opinion in Genetics & Development. 21: 474-83. PMID 21543223 DOI: 10.1016/J.Gde.2011.03.007  0.364
2011 Kondrashov N, Pusic A, Stumpf CR, Shimizu K, Hsieh AC, Xue S, Ishijima J, Shiroishi T, Barna M. Ribosome-mediated specificity in Hox mRNA translation and vertebrate tissue patterning. Cell. 145: 383-97. PMID 21529712 DOI: 10.1016/J.Cell.2011.03.028  0.46
2011 Kondrashov N, Pusic A, Stumpf C, Shimizu K, Hsieh A, Xue S, Ishijima J, Shiroishi T, Barna M. Specialized ribosomes control Hox mRNA translation and vertebrate tissue patterning Developmental Biology. 356: 102. DOI: 10.1016/J.Ydbio.2011.05.010  0.323
2010 Liu Q, Stumpf C, Wickens M, Haag E. Opposite sex-determining roles of PUF proteins in convergently evolved hermaphrodites are mediated by a conserved target mRNA Developmental Biology. 344: 435. DOI: 10.1016/J.Ydbio.2010.05.099  0.618
2009 Zhu D, Stumpf CR, Krahn JM, Wickens M, Hall TM. A 5' cytosine binding pocket in Puf3p specifies regulation of mitochondrial mRNAs. Proceedings of the National Academy of Sciences of the United States of America. 106: 20192-7. PMID 19918084 DOI: 10.1073/Pnas.0812079106  0.724
2009 Koh YY, Opperman L, Stumpf C, Mandan A, Keles S, Wickens M. A single C. elegans PUF protein binds RNA in multiple modes. Rna (New York, N.Y.). 15: 1090-9. PMID 19369425 DOI: 10.1261/Rna.1545309  0.637
2008 Stumpf CR, Opperman L, Wickens M. Chapter 14. Analysis of RNA-protein interactions using a yeast three-hybrid system. Methods in Enzymology. 449: 295-315. PMID 19215764 DOI: 10.1016/S0076-6879(08)02414-2  0.67
2008 Stumpf CR, Kimble J, Wickens M. A Caenorhabditis elegans PUF protein family with distinct RNA binding specificity. Rna (New York, N.Y.). 14: 1550-7. PMID 18579869 DOI: 10.1261/Rna.1095908  0.703
2002 Bernstein DS, Buter N, Stumpf C, Wickens M. Analyzing mRNA-protein complexes using a yeast three-hybrid system. Methods (San Diego, Calif.). 26: 123-41. PMID 12054889 DOI: 10.1016/S1046-2023(02)00015-4  0.764
2000 Kane MD, Jatkoe TA, Stumpf CR, Lu J, Thomas JD, Madore SJ. Assessment of the sensitivity and specificity of oligonucleotide (50mer) microarrays. Nucleic Acids Research. 28: 4552-7. PMID 11071945 DOI: 10.1093/Nar/28.22.4552  0.367
Show low-probability matches.